United Therapeutics (NASDAQ:UTHR) Stock Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of United Therapeutics Corporation (NASDAQ:UTHR). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in United Therapeutics stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $4.94 during trading hours on Wednesday, hitting $490.71. The company’s stock had a trading volume of 141,030 shares, compared to its average volume of 587,467. The company has a market capitalization of $21.13 billion, a P/E ratio of 18.56, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $490.81. The stock has a fifty day simple moving average of $443.02 and a 200-day simple moving average of $358.73.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the business posted $6.39 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on UTHR shares. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. HC Wainwright increased their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Wednesday, November 19th. Oppenheimer raised their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $505.00.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after purchasing an additional 15,312 shares in the last quarter. AQR Capital Management LLC lifted its position in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. raised its holdings in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares during the period. Darwin Global Management Ltd. bought a new stake in United Therapeutics in the third quarter worth $317,617,000. Finally, Assetmark Inc. raised its position in United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $464.76, for a total value of $5,112,360.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $17,094,337.56. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00. Following the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $3,818,382.48. This represents a 72.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 523,935 shares of company stock valued at $226,780,697. 10.30% of the stock is currently owned by insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.